Abstract PO5-03-11: Ultra-low Dose Nivolumab Added to Dose-Dense, Cisplatin-Based Neoadjuvant Chemotherapy in Locally Advanced, Borderline Operable Triple Negative Breast Cancer: A Matched Case-Control Study
Cancer Research(2024)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined